Outcome
| . | 3-month CCyR . | 6-month CCyR . | 12-month CCyR . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Yes . | No . | P . | Yes . | No . | P . | Yes . | No . | P . | |
| Total group | |||||||||
| 3-year EFS | 98 | 83 | < .001 | 97 | 72 | < .001 | 98 | 67 | < .001 |
| 3-year OS | 99 | 95 | .06 | 99 | 90 | < .001 | 99 | 94 | < .001 |
| IM 400 mg | |||||||||
| 3-year EFS | 92 | 81 | .12 | 97 | 74 | .001 | 98 | 72 | < .001 |
| 3-year OS | 100 | 88 | .046 | 100 | 87 | .09 | 100 | 88 | .046 |
| IM 800 mg | |||||||||
| 3-year EFS | 97 | 84 | .005 | 97 | 68 | < .001 | 98 | 58 | < .001 |
| 3-year OS | 98 | 97 | .93 | 99 | 92 | .001 | 99 | 100 | .03 |
| Second TKI | |||||||||
| 3-year EFS | 100 | 80 | < .001 | 99 | 67 | < .001 | 99 | NA | NA |
| 3-year OS | 100 | 100 | NA | 100 | 100 | NA | 100 | NA | NA |
| P (EFS/OS) | .07/.3 | .56/.81 | .9/.6 | ||||||
| . | 3-month CCyR . | 6-month CCyR . | 12-month CCyR . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Yes . | No . | P . | Yes . | No . | P . | Yes . | No . | P . | |
| Total group | |||||||||
| 3-year EFS | 98 | 83 | < .001 | 97 | 72 | < .001 | 98 | 67 | < .001 |
| 3-year OS | 99 | 95 | .06 | 99 | 90 | < .001 | 99 | 94 | < .001 |
| IM 400 mg | |||||||||
| 3-year EFS | 92 | 81 | .12 | 97 | 74 | .001 | 98 | 72 | < .001 |
| 3-year OS | 100 | 88 | .046 | 100 | 87 | .09 | 100 | 88 | .046 |
| IM 800 mg | |||||||||
| 3-year EFS | 97 | 84 | .005 | 97 | 68 | < .001 | 98 | 58 | < .001 |
| 3-year OS | 98 | 97 | .93 | 99 | 92 | .001 | 99 | 100 | .03 |
| Second TKI | |||||||||
| 3-year EFS | 100 | 80 | < .001 | 99 | 67 | < .001 | 99 | NA | NA |
| 3-year OS | 100 | 100 | NA | 100 | 100 | NA | 100 | NA | NA |
| P (EFS/OS) | .07/.3 | .56/.81 | .9/.6 | ||||||
IM indicates imatinib; and NA, not applicable